Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells
- 8 March 2021
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 118 (11)
- https://doi.org/10.1073/pnas.2016833118
Abstract
Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents or tumor-specific genetic deficiencies. There is also evidence suggesting that inhibition of the BER enzyme 8-oxoguanine DNA glycosylase-1 (OGG1), which initiates repair of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy-dG), could be useful in treating certain cancers. Specifically, in acute myeloid leukemia (AML), both the RUNX1-RUNX1T1 fusion and the CBFB-MYH11 subtypes have lower levels of OGG1 expression, which correlate with increased therapeutic-induced cell cytotoxicity and good prognosis for improved, relapse-free survival compared with other AML patients. Here we present data demonstrating that AML cell lines deficient in OGG1 have enhanced sensitivity to cytarabine (cytosine arabinoside [Ara-C]) relative to OGG1-proficient cells. This enhanced cytotoxicity correlated with endogenous oxidatively-induced DNA damage and Ara-C–induced DNA strand breaks, with a large proportion of these breaks occurring at common fragile sites. This lethality was highly specific for Ara-C treatment of AML cells deficient in OGG1, with no other replication stress-inducing agents showing a correlation between cell killing and low OGG1 levels. The mechanism for this preferential toxicity was addressed using in vitro replication assays in which DNA polymerase δ was shown to insert Ara-C opposite 8-oxo-dG, resulting in termination of DNA synthesis. Overall, these data suggest that incorporation of Ara-C opposite unrepaired 8-oxo-dG may be the fundamental mechanism conferring selective toxicity and therapeutic effectiveness in OGG1-deficient AML cells.Funding Information
- HHS | NIH | National Cancer Institute (R21 CA216551)
This publication has 49 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyaseCell Cycle, 2010
- OGG1 is a novel prognostic indicator in acute myeloid leukaemiaOncogene, 2009
- Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005Blood, 2009
- The efficiency and fidelity of 8-oxo-guanine bypass by DNA polymerases andNucleic Acids Research, 2009
- DNA damage alters DNA polymerase to a form that exhibits increased discrimination against modified template bases and mismatched primersNucleic Acids Research, 2008
- p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced deathBlood, 2008
- RPA and PCNA suppress formation of large deletion errors by yeast DNA polymerase δNucleic Acids Research, 2006
- Error Prone Translesion Synthesis Past γ-Hydroxypropano Deoxyguanosine, the Primary Acrolein-derived Adduct in Mammalian CellsOnline Journal of Public Health Informatics, 2002
- Leukemic cell line, KG-1 has a functional loss of hOGG1 enzyme due to a point mutation and 8-hydroxydeoxyguanosine can kill KG-1Oncogene, 2000